IRF8 Antibodies

Interferon regulatory factor 8 (IRF8)

Plays a role as a transcriptional activator or repressor (PubMed:25122610). Specifically binds to the upstream regulatory region of type I IFN and IFN-inducible MHC class I genes (the interferon consensus sequence (ICS)).

Plays a negative regulatory function in cells of the immune system. Involved in CD8(+) dendritic cell differentiation by forming a complex with the BATF-JUNB heterodimer in immune cells, resulting in recognition of AICE sequence (5'-TGAnTCA/GAAA-3'), an immune-specific regulatory element, followed by cooperative binding of BATF and IRF8 and activation of genes (By similarity).

Gene Information

Human
Gene Name:	IRF8
Uniprot:	Q02556
Entrez:	3394

Family

Belongs to:
IRF family

Alternative Names

ICSBP1; ICSBPH-ICSBP; interferon consensus sequence binding protein 1; Interferon consensus sequence-binding protein; interferon regulatory factor 8; IRF8; IRF-8ICSBP1

Molecular Weight

Mass (kDA):
48.356 kDA

Genomic Context

Human
Location:	16q24.1
Sequence:	16; NC_000016.10 (85899162..85922609)

Tissue Specificity

Predominantly expressed in lymphoid tissues.

Subcellular Localizations

Nucleus. Cytoplasm. In resting macrophages, localizes in the cytoplasm. Translocated in the nucleus upon IFN-gamma induction.

Diseases

• Leukemia
• Myeloid Leukemia
• Neoplasms
• Inflammation
• Malignant Neoplasms
• Leukemia, Myelocytic, Acute
• Myeloid Leukemia, Chronic
• Sclerosis
• Multiple Sclerosis
• Lupus Erythematosus, Systemic
• Autoimmune Reaction
• Immunologic Deficiency Syndromes
• Autoimmune Diseases

• B-cell Lymphomas
• Autoimmunity
• Lymphoma
• Tuberculosis
• Innate Immune Response
• Myeloproliferative Disease
• Sarcoma

Interacting Proteins

• IRF6

Pathways

• Cell Differentiation
• Cell Development
• Methylation
• Pathogenesis
• Dna Methylation
• Cell Cycle
• Immune Response
• Hypersensitivity
• Demethylation
• Cell Maturation
• B Cell Differentiation
• Osteoclast Differentiation
• Cytokine Production

• Cell Death
• Cell Growth
• Histone Acetylation
• Chromatin Remodeling
• Macrophage Activation
• Dendritic Cell Differentiation
• Phagocytosis

PTMs

• Methylation
• Phosphorylation
• Demethylation
• Acetylation

• Sumoylation
• Cleavage
• Dephosphorylation
• Ubiquitination

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/IRF8

Boster Bio: Best Uses Of The BTK Marker

If you are looking for an efficient method of gene expression analysis, you should read Boster Bio: Best Uses Of The BTK Marker. This guide will explain how to optimize your experiments, and answer any questions. This guide will also cover the various flow procedures, including Suicide and HSV-TK.

Suicide strategy

The study revealed that the IRF8WT promor can induce expression a reporter construct based upon the Ifnb promoter. The reporter construct did not express itself with the IRF8R294C-promoter. All data represent the mean of three independent experiments. SEM errors are considered error bars, and Student's T test was used to calculate p values.

HSV-TK

Boster biotechnology has the best use of IRF8 markers. This is because it can be used to create new antibody drugs. The IRF8 protein is present in all tissues and organs. It can be expressed in both animals and humans. This gene is susceptible for many mutations. Below are some of the mutations. It is also known as MCDRNGGRRL. It is a multi-functional gene that has many applications.

cytosine deaminase

The DNA-binding transcription element IRF8 plays a crucial role in myeloid cell lineage commitment. It has an IRF association Domain at its C-terminus that allows it to interact other transcription factors. This binding partner promotes the differentiation and maturation of myeloid cells into lymphoid tissues. IRF8-PU.1 is a transcription factor that binds to IRF8 and induces the expression of KLF4, which drives the development of Ly6C+ monocytes.

BATF-transduced cells express the IRF8 locus more than pMIG-transduced. FIG. 6D displays the labeling of the selected genes. 6D. The data were gathered from three biological experiments, one of which included the detection of IRF8 and IRF4 expression in human CD8+ T cells. The IRF8 gene expression was correlated with pMIG-seq signals and gene expression.

nitroreductase

The IRF8 oncogene is expressed in a wide variety of human cells. Although it is expressed predominantly in B cells it also has low levels within hematogones. This gene expression level was used in the classification of cases into acute myeloidleukemia (AMoL). The IRF8 gene can be used for monitoring patient response to targeted therapies and to detect malignant monoblasts. It can also be used to diagnose poor aspiration.

The IRF8 gene encodes an essential transcription factor for monocyte development and secretion cytokines from various APCs. It also promotes the differentiation and activation of CD4+ T cells, activates NK cells, and secretes IFN-g, a protein essential for antitumor immunity. Mutations of IRF8 can lead to significant deficiencies among monocytes and dendritic tissues.

It is important to identify the IRF8 marker for immunotherapy development. Patients with high levels of IRF8 have an increased survival rate compared to those with low levels. This gene expression has been linked to lower levels CD3++ T cells. It may also improve survival and be a biomarker that could help develop immunotherapy. It is possible that the IRF8 gene is more important than previously believed.

Caspase inducible

The RNA sequence data obtained from three biological experiments revealed the IRF8 gene. It was also shown to correlate with the expression of BATF, IRF4, and HKE. The expression patterns of the IRF8 locus show two distinct patterns. One is after stimulation and the second after no stimulation. This gene-expression profile has many applications. The IRF8 gene is a well-characterized candidate for the detection of cancer cells.

Cancer patients have high levels of the IRF8 gene in their blood. It is believed to control tumor development. IRF4 can be combined with BATF to inhibit cancer cell growth and promote the expression cytokines. IRF4 and BATF together can elicit an anti-cancer response in patients. However, the details of this effect are still not fully understood. Further research is needed to determine the most effective use for this gene in cancer cell treatment.